Compare Occidental Petroleum Corporation (OXY) vs 10X Genomics Inc (TXG) Price & Performance

Occidental Petroleum (OXY) trades at $58.21, down 0.21% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with a 30.32% net income margin and 21.46% ROE, while valuation metrics appear reasonable with a P/E of 17.17 and EV/EBITDA of 5.42. Recent earnings have consistently beaten expectations, and the company maintains a solid balance sheet with $2.13 billion in cash. Analyst consensus is bullish with a $71.40 price target, and the upcoming Q3 2026 earnings report on November 9 is a key catalyst.

OXY presents a compelling investment case with strong fundamentals, reasonable valuation, and positive analyst sentiment. The primary opportunities include continued earnings outperformance, debt reduction progress, and carbon management initiatives. Key risks include oil price volatility, declining revenue trends from $36.6B in 2022 to $21.6B in 2025, and execution challenges in the competitive energy sector. The stock offers upside potential to analyst targets but remains sensitive to commodity price movements.

10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.

The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.